NASDAQ:HRMY - Nasdaq - US4131971040 - Common Stock - Currency: USD
Overall HRMY gets a fundamental rating of 8 out of 10. We evaluated HRMY against 195 industry peers in the Pharmaceuticals industry. Both the health and profitability get an excellent rating, making HRMY a very profitable company, without any liquidiy or solvency issues. An interesting combination arises when we look at growth and value: HRMY is growing strongly while it also seems undervalued. With these ratings, HRMY could be worth investigating further for value and growth and quality investing!.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 14.49% | ||
ROE | 21.22% | ||
ROIC | 18.05% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 28.46% | ||
PM (TTM) | 20.54% | ||
GM | 78.34% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.22 | ||
Debt/FCF | 0.79 | ||
Altman-Z | 5.26 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 3.67 | ||
Quick Ratio | 3.64 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 12.26 | ||
Fwd PE | 7.83 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 8.32 | ||
EV/EBITDA | 6.32 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
32.11
+0.08 (+0.25%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 12.26 | ||
Fwd PE | 7.83 | ||
P/S | 2.48 | ||
P/FCF | 8.32 | ||
P/OCF | 8.27 | ||
P/B | 2.56 | ||
P/tB | 3 | ||
EV/EBITDA | 6.32 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 14.49% | ||
ROE | 21.22% | ||
ROCE | 24.06% | ||
ROIC | 18.05% | ||
ROICexc | 42.52% | ||
ROICexgc | 59.55% | ||
OM | 28.46% | ||
PM (TTM) | 20.54% | ||
GM | 78.34% | ||
FCFM | 29.77% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.22 | ||
Debt/FCF | 0.79 | ||
Debt/EBITDA | 0.67 | ||
Cap/Depr | 5.3% | ||
Cap/Sales | 0.17% | ||
Interest Coverage | 12.76 | ||
Cash Conversion | 94.51% | ||
Profit Quality | 144.92% | ||
Current Ratio | 3.67 | ||
Quick Ratio | 3.64 | ||
Altman-Z | 5.26 |